VX-950 (Vertex/Mitsubishi).

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2005 Italy English Journal:Current opinion in investigational drugs (London, England : 2000), volume 6 (issn: 1472-4472,

Copyright policy )

Authors: Summa V;

pmid: 16121690

handle: 11588/774136

VX-950 (Vertex/Mitsubishi).

- Summary
- Subjects
- Metrics

Abstract

Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection.

Country

Italy

Related Organizations

University Federico II of Naples
Italy

Keywords

Viral Proteases, Serine Endopeptidases, Viral Nonstructural Proteins, Nucleoside-Triphosphatase, Antiviral Agents, Patents as Topic, DEAD-box RNA Helicases, Structure-Activity Relationship, Animals, Humans, Protease Inhibitors, Oligopeptides

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average